Table 1: Ongoing clinical studies implicating valproic acid in monotherapies.

Dependences

 Alcohol abuse or dependence
 Alcoholism
 Cocaine dependence
 Marijuana abuse
 Substance abuse or dependence
 Substance withdrawal syndrome

Cancer

 Autoimmune lymphoproliferative syndrome
 Brain and central nervous system tumor
 Breast cancer
 CLL
 HTLV-I associated myelopathy
 MDS risk; AML
 Nasopharyngeal carcinoma
 Prostate cancer
 Sarcoma

Neurological disorders

 Alzheimer disease
 Amyotrophic lateral sclerosis
 Attention deficit hyperactivity disorder
 Autism
 Bipolar disorder
 Borderline personality disorder
 Cluster headache
 Dementia
 Depression
 Disruptive behavior
 Epilepsy
 Mania
 Migraine
 Mood disorder
 Neuralgia
 Phosphosensitive epilepsy
 Post traumatic stress disorder
 Progessive supranuclear palsy
 Resistant bipolar depression
 Schizophrenia
 Spinal muscular atrophy type 1

Others

 Asthma
 Hypersplenism; lymphadenopathy
 Hypoalbunemia
 Insulin resistance